CD44 and breast cancer: Pranlukast treatment decreased BC cell clonogenicity in the mammosphere formation assay, and also diminished CD44 and SOX2 expression, and tumorigenicity in vivo, showing that this drug reduces the CSC population in TNBC cells [138].